EUCTR2006-002585-19-GB进行中（未招募）1 期
A 24-week, randomised, open-label, 2-arm study to compare the tolerability and efficacy of saquinavir tablets with ritonavir versus lopinavir/ritonavir tablets in HIV 1 infected adults switching from Kaletra capsules - LoCKIT Study
Royal Free Hampstead NHS Trust0 个研究点目标入组 130 人开始时间: 2006年9月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Male or non-pregnant, non-nursing females ?18 years of age
- •- Seropositive for HIV-1
- •- On an antiretroviral combination of Kaletra® soft gel capsules with 2 nucleoside/nucleotide analogues for at least 6 months
- •- HIV-1 RNA viral load <50 copies/mL (2 consecutive measurements in the prior 6 months)
- •- No prior protease inhibitor exposure prior to commencing Kaletra® sof gel capsules.
- •- Ability and willingness to provide written informed consent and adhere to the study regimen
- •- Females of childbearing potential must have a documented negative serum or urine pregnancy test at screening/baseline and ensure that 2 reliable forms of contraception are being used, including a barrier method, for the duration of the study and for 90 days after the last dose of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Previous treatment with a PI based antiretroviral regimen prior to commencing Kaletra® soft gel capsules
- •- Patients with acute hepatitis B or C infection
- •- Significant renal dysfunction (creatinine clearance [CrCl] <60 mL/min) and/or hepatic impairment (aspartate aminotransferase/alanine aminotransferase [AST/ALT] >3 X ULN and/or documented liver cirrhosis)
- •- Any current known clinical or laboratory parameter of ACTG Grade 4. However, asymptomatic Grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate. Abnormalities deemed insignificant by the investigator must be discussed with the sponsor prior to enrollment.
- •- Evidence of active, untreated opportunistic infection, intercurrent illness, drug toxicity or any other condition such that in the judgment of the investigator the patient would not be able to take or continue a prescribed antiretroviral regimen
- •- Malignancy requiring chemotherapy or radiotherapy
- •- Known hypersensitivity to any of the prescribed antiretroviral drugs or formulation components
- •- Evidence of alcohol and/or drug or substance abuse that in the judgment of the investigator would likely result in the patient being unreliable in fulfilling the conditions of the protocol
- •- History of psychological illness or conditions that in the judgment of the investigator might interfere with the patient’s ability to understand the requirements of the study
- •- History of drug nonadherence that in the judgment of the investigator would result in the patient being unreliable in fulfilling the conditions of this protocol
- •- Patients who had received an investigational new drug within the last 4 weeks
- •- Currently taking, or anticipate taking during the course of the study, any drug contraindicated with the antiretroviral drugs they have been randomized to receive
研究者
相似试验
已完成
不适用
This is a clinical trial wherein the efficacy and safety of Curcumin will be studied in Canker sore and gingivitis.CTRI/2017/01/007670Sami Labs Limited60
进行中（未招募）
不适用
Efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patientsType II Diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002090-36-DKsanofi-aventis Recherche et Développement310
进行中（未招募）
不适用
Efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patientsType II Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002090-36-LTsanofi-aventis Recherche et Développement310
进行中（未招募）
不适用
Efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patientsType II Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002090-36-CZsanofi-aventis Recherche et Développement310
进行中（未招募）
不适用
Efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patientsType II Diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002090-36-SEsanofi-aventis Recherche et Développement310